摘要
目的探讨利拉鲁肽对2型糖尿病非酒精性脂肪肝的治疗作用及可能机制。方法回顾性分析我院2016年5月-2018年12月期间收治的60例2型糖尿病非酒精性脂肪肝患者的临床资料,按治疗方式分为观察组与对照组,对照组患者接受二甲双胍治疗,观察组患者接受利拉鲁肽治疗,比较两组治疗总有效率、血糖、血脂、氧化应激及肝功能指标。结果观察组总有效率93.33%,高于对照组的66.67%;治疗后,观察组HbA1c、2hPG、FPG低于对照组;观察组TG、TC、LDL-C低于对照组,HDL-C高于对照组;观察组AST、ALT低于对照组;观察组患者CAT、SOD、T-AOC水平均高于对照组,且MDA、LHP、AOPPs水平均低于对照组,差异有统计学意义(P<0.05)。结论利拉鲁肽治疗2型糖尿病非酒精性脂肪肝的疗效确切,能有效控制患者血糖、血脂水平,改善肝功能指标。
Objective To investigate the therapeutic effect and possible mechanism of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes. Methods The clinical data of 60 patients with type 2 diabetes nonalcoholic fatty liver disease admitted to our hospital from May 2016 to December 2018 were retrospectively analyzed. The patients were divided into observation group and control group according to the treatment mode. The control group received metformin treatment, patients in the observation group received liraglutide treatment, and the total effective rate, blood glucose, blood lipids and liver function indexes of the two groups were compared. Results The total effective rate of the observation group was 93.33%, which was higher than that of the control group(66.67%). After treatment, the HbA1c, 2hPG and FPG of the observation group were lower than the control group;the TG, TC and LDL-C of the observation group were lower than the control group, HDL-C The control group was lower than the control group. The levels of CAT, SOD, and T-AOC in the observation group were higher than those in the control group, and the levels of MDA, LHP, and AOPPs were lower than those in the control group(P <0.05). Conclusion Liraglutide is effective in the treatment of type 2 diabetes nonalcoholic fatty liver disease, which can effectively control blood sugar and blood lipid levels and improve liver function.
作者
黄华清
向爱民
赖大行
陈颖斌
周露
HUANG Huaqing;XIANG Aimin;LAI Dahang(Kaiping City,Traditional Chinese Medicine Hospital,Kaiping,Guandong Prvince,529300,China)
出处
《江西医药》
CAS
2020年第4期382-385,389,共5页
Jiangxi Medical Journal
基金
广东省江门市卫生计生局科学技术研究项目,编号18A013。
